BioSpace News Archive

Quest Diagnostics Incorporated, the world’s leading provider of diagnostic information services, announced preliminary financial results for the second quarter ended June 30, 2020.

NovaBay® Pharmaceuticals, Inc. announces testing results from an independent third-party laboratory confirming that Avenova®, NovaBay’s proprietary formulation of pure hypochlorous acid, kills SARS-CoV-2.

Calithera Biosciences, Inc., a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, announced that it has dosed the first patients in its Phase 1b clinical trial of the arginase inhibitor CB-280 in adult patients with cystic fibrosis and chronic airway infection.

Axsome Therapeutics, Inc., a biopharmaceutical company developing novel therapies for the management of central nervous system disorders, announced that it has completed a successful pre-New Drug Application meeting with the U.S. Food and Drug Administration for AXS-05 for the treatment of major depressive disorder.

Mateon Therapeutics, a leading developer of TGF-β therapeutics, announced that it will fund observational studies for Artemisinin, an herbal supplement, that demonstrated potent in vitro activity against SARS-CoV-2, the COVID-19 virus.

Characterization of fadraciclib published in peer-reviewed journal shows specificity against CDK2 and CDK9 and enablement of apoptosis of cancer cells driven by MCL1, cyclin E and/or MYC

Angelini Pharma obtains exclusive development, manufacturing and commercialization rights to OV101 (gaboxadol) for the potential treatment of Angelman syndrome in the European Union and other countries in the European Economic Area (Switzerland, Turkey and the United Kingdom) and Russia

Versatile designs, intuitive interfaces and precision systems provide patients with proven respiratory therapies

Premier Inc., through its ProvideGx™ program, has partnered with Fresenius Kabi to supply Diprivan® injectable emulsion, USP to healthcare providers, helping to stabilize the long-term supply of a medication vital for COVID-19 patient care.

Cerevel Therapeutics, a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced the appointment of Kathleen W. Tregoning as chief corporate affairs officer.